Alpha-Synuclein Seed Amplification for Differential Synucleinopathy Diagnosis

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current diagnostic methods for synucleinopathies, such as Parkinson's disease and Lewy body dementia, lack a reliable and specific biological test for misfolded alpha-synuclein protein, leading to inaccurate diagnoses and challenges in differentiating between related neurodegenerative disorders.

Innovation Solution

A method involving a reaction buffer with monomeric alpha-synuclein and a fluorophore, combined with intermittent shaking and resting cycles, to detect misfolded alpha-synuclein protein in biological samples, using specific conditions to minimize false positives and enhance sensitivity and specificity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If clinical diagnosis methods are used for synucleinopathies, then comprehensive evaluation can be performed, but diagnostic accuracy varies significantly (26%-88%) and cannot provide objective biological confirmation

Engineering Contradiction:
Improvediagnostic accuracyVSAvoidobjective biological confirmation
Core Design Contradiction:
Measurement precisionVSReliability

Solution Approach 1:

The patent replaces subjective clinical evaluation methods with an objective biochemical detection system. The seed amplification assay uses fluorescent detection to identify misfolded alpha-synuclein seeds in biological samples, providing quantifiable and reproducible results that eliminate variability in clinical judgment and provide objective biological confirmation of synucleinopathy diagnosis.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces an intermediary amplification process between the presence of misfolded proteins and their detection. The seed amplification assay uses normal alpha-synuclein as a substrate that amplifies the signal from trace misfolded seeds through cyclic aggregation and fragmentation, making undetectable amounts of pathological proteins visible through fluorescent measurement.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Measurement precision

If misfolded protein detection assays are performed, then sensitivity can be improved, but false positives from spontaneous aggregation increase

Engineering Contradiction:
Improvedetection sensitivityVSAvoidfalse positives
Core Design Contradiction:
Measurement precisionVSObject-generated harmful factors

Solution Approach 1:

The patent employs periodic shaking and resting cycles during the incubation process. The shaking phase promotes fragmentation of aggregated proteins into smaller seeds, while the resting phase allows normal alpha-synuclein to aggregate on existing misfolded seeds. This periodic action amplifies the signal from true pathological seeds while the specific buffer conditions suppress spontaneous aggregation that would cause false positives.

Inventive Principle:
Principle #19Periodic action

Solution Approach 2:

The patent optimizes specific parameters of the reaction buffer including pH (7.0-8.5), ionic strength, and composition to create conditions that favor specific amplification of misfolded seeds while suppressing spontaneous aggregation. These parameter changes create a selective environment where only pathological proteins undergo cyclic amplification, distinguishing true positives from false positives.

Inventive Principle:
Principle #35Parameter changes

3Device complexity

If conventional detection methods are used, then simplicity can be maintained, but inability to differentiate between synucleinopathy types persists

Engineering Contradiction:
Improveassay simplicityVSAvoiddifferential diagnosis capability
Core Design Contradiction:
Device complexityVSMeasurement precision

Solution Approach 1:

The patent creates a universal assay platform that can detect and differentiate multiple types of synucleinopathies using the same basic methodology. The seed amplification assay works for Lewy body diseases, multiple system atrophy, and other alpha-synuclein disorders, providing both general detection and specific differentiation through pattern recognition and quantitative analysis of amplification kinetics.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method provides a highly sensitive and specific assay for detecting misfolded alpha-synuclein, enabling accurate diagnosis of synucleinopathies, differential diagnosis between Lewy fold and MSA synucleinopathies, and monitoring disease progression, with high sensitivity and specificity.

Implementation Method 1

a fluorophore, to form a reaction mixture; incubating the reaction mixture with intermittent shaking/resting cycles; subjecting the reaction mixture to excitation; determining the fluorescence intensity of the reaction mixture

Methodology Applied
Scientific EffectFluorescence: Fluorescence

Data Source

PatentEP4682539A1Method for detecting misfolded alpha-synuclein protein in biological samples to determine the presence of synucleinopathies in an individual
Publication Date: 2026.01.21 MODAG GMBH
  • EP4682539A1 patent drawingFigure 1a~1d
  • EP4682539A1 patent drawingFigure 2
  • EP4682539A1 patent drawingFigure 3

AI summary

The invention relates to a method for detecting misfolded alpha-synuclein protein in a biological sample to determine the presence of synucleinopathies in an individual. The method provided by the present invention can also be used for differential diagnosis of Lewy fold synucleinopathies from MSA synucleinopathies as well as for monitoring of the disease progression in individuals. Moreover, a kit for detecting misfolded αSyn protein in biological samples is provided.